| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | AXPAXLI (OTX-TKI) Wet age-related macular degeneration (wet AMD) | Phase 3 | — | Subscribe to access the data. | Small Molecules | Ophthalmologic System | |
Phase 3 topline data readout example | AXPAXLI (OTX-TKI) Wet age-related macular degeneration (wet AMD) | Phase 3 | — | Subscribe to access the data. | Small Molecules | Ophthalmologic System | |
Phase 3 topline data readout example | AXPAXLI (OTX-TKI) Wet age-related macular degeneration (wet AMD) | Phase 3 | — | Subscribe to access the data. | Small Molecules | Ophthalmologic System |
Recent Updates
Recently added Catalysts
Ocular Therapeutix, Inc.$9.64
+0.17 (+1.8%)
C 56Pipeline Score Fair Value Pharma · Commercial
Market Cap
1.80 B
EPS
-1.46
P/E Ratio
-
Value Trade
16.90 M
SEC Financials
Q1 2026Dilution Risk
Revenue
10.79 M
R&D Expenses
66.21 M
Operating CF
-65.99 M
Total Assets
732.53 M
Total Liabilities
150.96 M
Equity
581.57 M
D/E Ratio
12,345
-11.41 %
Week
-13.73 %
1 Month
17.74 %
3 Month
-29.48 %
6 Month
-42.57 %
5 Year
-36.69 %
All Time
Cash Data
Cash Position
666.70 M
Monthly Burn
22.00 M
Runway
28.3 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
1.83 M
52 Week Range
6.23 - 16.44
% held by Insiders
8.42 %
% held by Institutions
89.22 %
Enterprise Value
1.21 B
Total Shares
217.61 M
Short %
14.77 %
Float Shares
179.10 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ocular Therapeutix, Inc.
533Total events
8Upcoming
102Tier-1 (high impact)
2015 – 2027Coverage
Upcoming catalysts 8
Jul 15, 2026
T3Poster Presentation
Anti-VEGF Treatment Patterns and Long-Term Vision Outcomes in nAMD in the IRIS Registry at ASRS 2026
Jul 16, 2026
T2Oral Presentation
Intravitreal Axitinib Hydrogel (OTX-TKI) in nAMD: Efficacy and Safety Results from Phase 3 SOL-1 Trial at ASRS 2026
Jul 16, 2026
T2Oral Presentation
Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control at ASRS 2026
Event history 525
Jun 13, 2026
◆Oral PresentationOTX-TKIPresentation
HELIOS Program Update on OTX-TKI in Nonproliferative Diabetic Retinopathy
nonproliferative diabetic retinopathysource ↗
May 26, 2026
May 19, 2026
◆Oral PresentationPresentation
The Royal College of Ophthalmologists Annual Congress 2026 Symposium: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control
neovascular age-related macular degenerationsource ↗
May 15, 2026
◆Oral PresentationOTX-TKIPresentation
Retina World Congress 2026: Update on Latest TKI data from the OTX-TKI program
May 15, 2026
◆Oral PresentationPresentation
Retina World Congress 2026 Symposium: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control
neovascular age-related macular degenerationsource ↗
May 14, 2026
◆Oral PresentationPresentation
Retina World Congress 2026 Presentation: Ocular Therapeutix: Retina Experience Redefined
May 12, 2026
May 7, 2026
◆Poster PresentationPresentation
Real-World Anti-VEGF Treatment Utilization and Vision Outcomes in Neovascular Age-Related Macular Degeneration: Analysis of the Vestrum Database
neovascular age-related macular degenerationsource ↗
Drug Pipeline Intelligence
C56
Pipeline Score $1.8B
Pipeline ValueFair Value
Valuation Signal11
Drugs Scored1.0x
rNPV / MCap Top 84%
Micro Cap (rank 146 of 906)
Percentile RankOcular Therapeutix, Inc. carries a moderate pipeline score (56/100), with $4.5B risk-adjusted pipeline value, led by OTX-TKI in Neovascular Age-related Macular Degeneration (Phase 3), across $80B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OTX-TKI Small molecule | Neovascular Age-related Macular Degeneration | Phase 3 | NCT06495918 | 44% | $1.6B | ACTIVE NOT_RECRUITING | 1,198 | FAST | B (69) | Jan 8, 2027 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AXPAXLI | wet AMD | Phase 3 | 2026-04-13 | median time of 39 weeks and 46 weeks to≥30 and≥75 uM increases from Week 8; median time to ≥30 uM Central Subfield Thickness (CSFT) increase from Week 8 was 39 weeks in the AXPAXLI group and 16 weeks in the aflibercept (2 mg) group, a 23-week difference; estimated hazard ratio of 0.7 Read More | Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD Read More | |
AXPAXLI | wet AMD | Phase 3 | 2026-04-13 | median time of 39 weeks and 46 weeks to≥30 and≥75 uM increases from Week 8; median time to ≥30 uM Central Subfield Thickness (CSFT) increase from Week 8 was 39 weeks in the AXPAXLI group and 16 weeks in the aflibercept (2 mg) group, a 23-week difference; estimated hazard ratio of 0.7 Read More | Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD Read More | |
AXPAXLI | wet AMD | Phase 3 | 2026-04-13 | median time of 39 weeks and 46 weeks to≥30 and≥75 uM increases from Week 8; median time to ≥30 uM Central Subfield Thickness (CSFT) increase from Week 8 was 39 weeks in the AXPAXLI group and 16 weeks in the aflibercept (2 mg) group, a 23-week difference; estimated hazard ratio of 0.7 Read More | Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OCUL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OCUL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
OCULOcular Therapeutix™ to Participate in July Scientific and Investor Conferences
Ocular Therapeutix, Inc. announced its participation in several scientific and investor conferences in July 2026. Key presentations will focus on advancements in retinal therapies, including results from the Phase 3 SOL-1 trial for AXPAXLI. The company aims to redefine the retina experience through innovative treatments and ongoing clinical trials.
Read more →OCULOcular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
Ocular Therapeutix announced its plans to submit a New Drug Application (NDA) for AXPAXLI in wet AMD by Q4 2026, based on positive SOL-1 trial data. The company will conduct an interim safety analysis for the SOL-R trial to meet FDA requirements. AXPAXLI aims to differentiate itself from existing treatments like aflibercept, with a new secondary endpoint added to the SOL-R trial. The company is also streamlining its diabetic retinopathy program to focus on the HELIOS-3 trial.
Read more →OCULOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. has announced the granting of inducement awards to seven newly hired non-executive employees, compliant with Nasdaq’s listing rules. These equity awards include stock options and restricted stock units, aimed at encouraging acceptance of employment. The stock options have a ten-year term with a four-year vesting period, while the restricted stock units vest over three years. Ocular is also advancing its treatment pipeline, particularly with AXPAXLI in Phase 3 trials.
Read more →OCULOcular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
Ocular Therapeutix, Inc. announced its participation in the Clinical Trials at the Summit 2026, held on June 12-13 in Las Vegas, Nevada. The event includes presentations on the company's investigational product AXPAXLI, aimed at treating neovascular AMD and diabetic retinal diseases. Significant discussions will focus on the safety and efficacy outcomes of OTX-TKI. This participation emphasizes Ocular's dedication to innovation and leadership in retinal disease therapies.
Read more →OCULOcular Therapeutix™ to Host Investor Day on June 17, 2026
Ocular Therapeutix will host an Investor Day on June 17, 2026, in New York City, featuring presentations from company leadership and retinal disease experts. The event will cover the NDA submission plan for AXPAXLI in wet AMD, updates on ongoing trials, and commercialization strategies. A live Q&A session and networking reception will conclude the event.
Read more →OCULOcular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
Ocular Therapeutix reported strong financial results for Q1 2026, highlighted by positive outcomes from the Phase 3 SOL-1 trial for AXPAXLI in wet AMD. The company plans to submit a New Drug Application (NDA) based on these results. Ocular is also advancing its other trials, including SOL-R and HELIOS-3, while maintaining a robust cash position to support its operations into 2028.
Read more →OCULOcular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
Ocular Therapeutix has enrolled the first patient in the SOL-X long-term extension trial for AXPAXLI, targeting wet age-related macular degeneration (AMD). This trial follows the successful SOL-1 Phase 3 trial and aims to evaluate long-term safety and efficacy while reducing treatment burden. The company believes that continuous VEGF suppression could significantly improve patient outcomes.
Read more →OCULOcular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
Ocular Therapeutix, Inc. will hold a conference call on May 5, 2026, to discuss its first quarter financial results and recent business developments. The call will feature insights into the company's ongoing Phase 3 clinical trials for its product AXPAXLI, aimed at treating retinal diseases. Interested parties can access the live and archived webcasts through the company's website.
Read more →OCULOcular Therapeutix™ to Participate in May Scientific and Investor Conferences
Ocular Therapeutix, Inc. announced its participation in several scientific and investor conferences in May 2026. Key events include the Bank of America Health Care Conference and the ARVO Annual Meeting, where the company will present findings related to retinal disease treatments. The presentations will highlight the efficacy and safety of its investigational product AXPAXLI, currently in Phase 3 trials.
Read more →OCULOcular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
Ocular Therapeutix announced positive Week 52 data from the SOL-1 Phase 3 trial of AXPAXLI for wet AMD. The trial demonstrated superior durability and sustained disease control compared to aflibercept. The company plans to submit a New Drug Application based on these findings, aligning with FDA expectations for approval based on a single pivotal trial.
Read more →OCULOcular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
Ocular Therapeutix announced its participation in several scientific conferences in April 2026 to present additional data from the SOL-1 Phase 3 trial of AXPAXLI for wet AMD. Key presentations will occur at the Vit-Buckle Society Meeting and the Congreso Nacional de Oftalmologia in Argentina. The company aims to enhance understanding of its investigational treatments.
Read more →OCULOcular Therapeutix™ to Participate in March Investor Conferences
Ocular Therapeutix, Inc. announced its participation in several investor conferences in March 2026. Key events include the TD Cowen Health Care Conference and the Jefferies Biotech on the Beach Summit, where CEO Pravin U. Dugel will present. The company is also advancing its investigational product AXPAXLI for retinal diseases in Phase 3 clinical trials.
Read more →OCULOcular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations
Ocular Therapeutix will present detailed results from the SOL-1 Phase 3 trial for AXPAXLI at the 49th Macula Society Annual Meeting on February 27, 2026. An investor webcast is scheduled for March 2, 2026, to discuss these findings. The SOL-1 trial focuses on treating wet age-related macular degeneration, showcasing Ocular's commitment to advancing retinal therapies.
Read more →OCULOcular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Ocular Therapeutix is facing scrutiny after a significant stock price drop of approximately 27% following the release of topline results from its SOL-1 Phase 3 trial. Johnson Fistel, PLLP is investigating potential claims on behalf of investors who may have suffered losses related to Ocular's disclosures. The trial results indicated encouraging patient outcomes, yet the market's negative reaction raises concerns about the company's compliance with federal securities laws. Investors are encouraged to reach out to Johnson Fistel for more information regarding their rights and potential recovery options.
Read more →OCULOcular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD
Ocular Therapeutix announced positive results from the SOL-1 Phase 3 trial of AXPAXLI for wet AMD, demonstrating significant superiority over aflibercept in maintaining vision. At Week 36, 74.1% of subjects on AXPAXLI maintained vision compared to 55.8% on aflibercept. The drug showed a favorable safety profile with no serious adverse events. Ocular plans to submit a New Drug Application based on these results.
Read more →OCULOcular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026
Ocular Therapeutix, Inc. has announced that it will host a webcast on February 17, 2026, to review the topline results of its SOL-1 Phase 3 superiority clinical trial for AXPAXLI, targeting wet age-related macular degeneration. Detailed results from the trial will be presented at the 49th Macula Society Annual Meeting later that month. The webcast will allow stakeholders to access both live and archived information, reflecting Ocular's commitment to transparency in their clinical progress.
Read more →OCULOcular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 6, 2026
Ocular Therapeutix has granted inducement equity awards to five new non-executive employees as part of its 2019 Inducement Stock Incentive Plan. The awards include stock options and restricted stock units, with vesting schedules tied to continued employment. This move aligns with the company's commitment to enhancing its workforce as it progresses with its clinical trials for retinal diseases.
Read more →OCULOcular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. has announced the granting of inducement awards to five newly hired non-executive employees as part of its 2019 Inducement Stock Incentive Plan. The equity awards include stock options to purchase 13,850 shares and restricted stock units for 4,600 shares, all subject to vesting conditions based on continued employment. This move reflects the company's strategy to strengthen its workforce while adhering to Nasdaq regulations.
Read more →OCULOcular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Ocular Therapeutix reported its financial results for Q4 and full year 2025, highlighting a decrease in total net revenue and an increased net loss. The company is preparing for the presentation of SOL-1 Phase 3 trial results at the upcoming Macula Society Annual Meeting and plans to submit an NDA for AXPAXLI in wet AMD, pending positive outcomes. Despite financial challenges, Ocular maintains a strong cash position to support ongoing clinical trials.
Read more →OCULOcular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 23, 2026
Ocular Therapeutix has granted inducement awards to David W. Robinson, its new Global Chief Commercial Officer, as part of its 2019 Inducement Stock Incentive Plan. The awards include stock options for 416,000 shares and restricted stock units for 136,000 shares, both subject to vesting conditions. Ocular's investigational product AXPAXLI is currently in Phase 3 trials for wet AMD and NPDR.
Read more →OCULOcular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
Ocular Therapeutix has appointed David W. Robinson as Global Chief Commercial Officer. Robinson, known for his role in the successful launch of EYLEA at Regeneron, will lead the commercialization of AXPAXLI, aimed at treating wet age-related macular degeneration and diabetic retinopathy. His extensive experience in ophthalmology is expected to bolster Ocular's market presence.
Read more →OCULOcular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD
Ocular Therapeutix plans to accelerate the NDA submission for AXPAXLI in wet AMD, contingent on positive data from the SOL-1 trial expected in Q1 2026. The company aims to leverage the 505(b)(2) regulatory pathway, potentially expediting the review process. If successful, AXPAXLI could become the first TKI approved for wet AMD, offering improved treatment durability.
Read more →OCULOcular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR
Ocular Therapeutix has announced the randomization of the first patient in the HELIOS-3 Phase 3 trial for AXPAXLI, targeting non-proliferative diabetic retinopathy (NPDR). This trial, alongside HELIOS-2, aims to evaluate the efficacy of AXPAXLI, which could significantly improve treatment options for NPDR patients. The studies utilize a novel diabetic retinopathy severity scale as a primary endpoint.
Read more →OCULOcular Therapeutix™ to Participate in November and December Investor Conferences
Ocular Therapeutix, Inc. announced its participation in upcoming investor conferences in November and December 2025. The conferences include the Jefferies Global Healthcare Conference in London and the Piper Sandler 37th Annual Healthcare Conference in New York. CEO Pravin U. Dugel will present at both events, highlighting the company's advancements in retinal disease treatments.
Read more →OCULOcular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights
Ocular Therapeutix reported its third quarter 2025 financial results, highlighting significant advancements in its AXPAXLI program for retinal diseases. The company achieved its target randomization in the SOL-R trial and anticipates topline data for SOL-1 in early 2026. Despite a decrease in net revenue and an increased net loss, Ocular maintains a strong cash position to support ongoing and future clinical trials.
Read more →OCULOcular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
Ocular Therapeutix has successfully reached the target randomization of 555 subjects in its SOL-R trial for AXPAXLI, an investigational treatment for wet AMD. The trial aims to provide data supporting the drug's adoption into clinical practice with a dosing regimen of every six months. Topline data is anticipated in the first half of 2027, contributing to a potential NDA submission.
Read more →OCULOcular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025
Ocular Therapeutix, Inc. has announced a conference call for November 4, 2025, to discuss its third quarter financial results for the period ending September 30, 2025. This event will provide insights into the company's recent business progress and financial performance. Ocular Therapeutix is actively involved in clinical trials for its investigational product AXPAXLI and the development of other pipeline candidates.
Read more →OCULOcular Therapeutix™ to Participate in Upcoming Scientific Conferences
Ocular Therapeutix, Inc. announced its participation in several upcoming scientific conferences in October 2025, including the American Academy of Optometry and the American Academy of Ophthalmology. The company is advancing its investigational product AXPAXLI for retinal diseases, currently in Phase 3 trials for wet AMD. Additionally, Ocular is preparing to initiate a Phase 3 program for non-proliferative diabetic retinopathy.
Read more →OCULOcular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock
Ocular Therapeutix has announced the pricing of an underwritten offering of 37,909,018 shares of common stock at $12.53 per share, aiming to raise approximately $475 million. The proceeds will support ongoing clinical trials for AXPAXLI in treating wet AMD and NPDR, among other corporate purposes. The offering is expected to close on or about October 1, 2025.
Read more →OCULOcular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint
Ocular Therapeutix hosted an Investor Day to showcase progress in its AXPAXLI program, particularly in the SOL-1 trial for wet AMD and upcoming HELIOS trials for diabetic retinopathy. The company highlighted a novel primary endpoint aligned with FDA guidelines, aiming to enhance treatment efficacy and patient outcomes. Topline data for SOL-1 is expected in Q1 2026, while HELIOS-2 and HELIOS-3 trials are set to begin soon.
Read more →OCULOcular Therapeutix TM Announces Pricing of Underwritten Offering of Common Stock BEDFORD, MA
Ocular Therapeutix has announced the pricing of an underwritten offering of 37,909,018 shares of common stock at $12.53 per share, raising approximately $475 million. The proceeds are intended to fund planned clinical studies for their investigational product AXPAXLI, specifically for wet age-related macular degeneration and non-proliferative diabetic retinopathy. The offering is set to close on October 1, 2025, pending customary closing conditions.
Read more →OCULOcular Therapeutix™ to Host Investor Day on September 30, 2025
Ocular Therapeutix will host an Investor Day on September 30, 2025, in New York City, focusing on its AXPAXLI wet AMD program and future strategies for NPDR and DME. The event will feature presentations from senior leadership and discussions with global retinal disease experts. A live Q&A session and networking reception will conclude the event.
Read more →OCULOcular Therapeutix™ to Participate in September Investor and Scientific Conferences
Ocular Therapeutix, Inc. (NASDAQ: OCUL) has announced its participation in several key investor and scientific conferences throughout September 2025. Notable appearances include the Morgan Stanley 23rd Annual Global Healthcare Conference and the Baird 2025 Global Healthcare Conference, where the company's Executive Chairman will present. Additionally, Ocular will feature at the EURETINA congress with presentations focused on retinal disease treatment advancements. The upcoming events highlight Ocular's commitment to redefining the retina experience through ongoing clinical trials and innovative product candidates.
Read more →OCULOcular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR
Ocular Therapeutix has announced that it received FDA agreement under a Special Protocol Assessment for the clinical trial design of AXPAXLI, aimed at treating non-proliferative diabetic retinopathy (NPDR). This milestone is considered crucial for the company's strategy to expand AXPAXLI's use beyond wet AMD. The agreement ensures alignment with FDA requirements, indicating a clear regulatory pathway for the planned trial. Medical experts believe AXPAXLI's potential once-a-year dosing could significantly impact the management of diabetic retinopathy, a common cause of vision loss among adults.
Read more →OCULOcular Therapeutix Reports Second Quarter 2025 Financial Results and Business Highlights Outstanding patient retention and clinical execution in complementary AXPAXLI SOL trials for wet AMD SOL-1 remains on track for 1Q
Ocular Therapeutix has announced its financial results for the second quarter of 2025, highlighting strong patient retention in its AXPAXLI clinical trials for wet AMD. The company remains on track to report topline data for the SOL-1 trial in Q1 2026 and has simplified the protocol for the SOL-R trial. A recent capital raise of approximately $97 million enhances its financial position, allowing it to maintain operations into 2028. The upcoming Investor Day on September 30, 2025, will provide further insights into the company's pipeline and strategies.
Read more →OCULOcular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
Ocular Therapeutix, Inc. has announced a conference call and webcast scheduled for August 5, 2025, to discuss its second quarter financial results and business developments. The company, which focuses on redefining the retina experience, is actively progressing its investigational candidate AXPAXLI in Phase 3 clinical trials for wet age-related macular degeneration. Additionally, the webcast will be available for public access and archived for future viewing, reinforcing the company’s commitment to transparency with shareholders.
Read more →OCULOcular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
Ocular Therapeutix, Inc. has announced the launch of its new corporate branding, signaling its transformation into a retina-focused company. This branding aims to represent the company's commitment to redefining the treatment experience for retinal diseases, notably wet age-related macular degeneration (AMD). Ocular's investigational therapy, AXPAXLI, is intended to improve treatment durability and outcomes for patients affected by retinal disorders. The new branding will be prominently featured at the upcoming American Society of Retina Specialists conference.
Read more →OCULOcular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
Ocular Therapeutix has announced its participation in Clinical Trials at the Summit 2025, scheduled for June 21 in Las Vegas, NV. The company will present key findings on its investigational product OTX-TKI for wet AMD and its safety and efficacy for diabetic retinopathy. Presentations will be made by prominent members of the company, showcasing their advancements and insights into retinal therapies.
Read more →OCULOcular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration
Ocular Therapeutix has announced that it will close enrollment for its SOL-R trial, evaluating the efficacy of AXPAXLI in treating wet age-related macular degeneration (wet AMD). The SOL-R trial is significant as it follows the successful randomization of patients in the SOL-1 trial. Together, these trials are designed to support a New Drug Application for AXPAXLI, with the potential for demonstrating non-inferiority to existing treatments. The rapid pace of enrollment and adherence in both trials suggests strong interest and collaboration from the medical community.
Read more →OCULOcular Therapeutix™ to Participate in Upcoming Investor Conferences
Ocular Therapeutix, Inc. (NASDAQ: OCUL) has announced its participation in several investor conferences occurring in May 2025. The events include the RBC Capital Markets Global Healthcare Conference and the HC Wainwright BioConnect Investor Conference, both featuring presentations by CEO Pravin U. Dugel, MD. Additionally, the company will host one-on-one investor meetings at the Mizuho Neuro & Ophthalmology Summit and present at the Stifel Virtual Ophthalmology Forum. Ocular's investigational therapy AXPAXLI is currently in Phase 3 trials for wet age-related macular degeneration.
Read more →OCULOcular Therapeutix Reports First Quarter 2025 Results and Business Highlights AXPAXLI SOL trials for wet AMD progressing rapidly following recent updates to accelerate and enhance the registrational program Following pos
Ocular Therapeutix reported its financial results for Q1 2025, highlighting significant progress in its AXPAXLI trials for wet AMD and positive FDA feedback for NPDR. The company reported a cash balance of $349.7 million, suggesting a stable financial position until 2028. Despite a 27.6% decline in total net revenue, mainly due to DEXTENZA sales, the company aims for improved revenue in upcoming quarters driven by strategic shifts in sales efforts. The ongoing trials are on track for topline data readout in Q1 2026.
Read more →OCULOcular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences
Ocular Therapeutix, Inc. announced their participation in several investor and scientific conferences scheduled for May 2025. Key events include presentations at the Citizens JMP Life Sciences Conference and the Bank of America Global Healthcare Conference, highlighting important advancements in retinal disease treatments. Additionally, the company will showcase its investigational product AXPAXLI at key scientific gatherings like ARVO 2025, reinforcing its focus on innovation in retinal care.
Read more →OCULOcular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025
Ocular Therapeutix, Inc. has announced that it will release its first quarter 2025 financial results on May 5, 2025, at 7:00 AM Eastern Time. Unlike previous quarters, the company will not host a conference call for this announcement but will continue regular quarterly earnings calls starting with its second quarter results. The company is involved in clinical trials for its investigational products, including AXPAXLI, aimed at retinal diseases and DEXTENZA, which addresses post-surgical inflammation.
Read more →OCULOcular Therapeutix™ to Participate in Two Investor Conferences in April
Ocular Therapeutix, Inc. has announced its participation in two investor conferences in April 2025, including the 24th Annual Needham Virtual Healthcare Conference and the Piper Sandler Spring Biopharma Symposium. CEO Pravin U. Dugel will present at the Needham conference. The company is currently advancing its product candidate AXPAXLI for retinal disease and continues to develop other treatments using its proprietary hydrogel technology. These events are aimed at enhancing investor relations and showcasing the company's advancements in biopharmaceuticals.
Read more →OCULOcular Hypertension Pipeline Insight 2025: Comprehensive Insights for 50+ Companies and 75+ Pipeline Drugs in the Ocular Hypertension Pipeline Landscape
The report titled "Ocular Hypertension - Pipeline Insight, 2025" outlines the current landscape of ocular hypertension therapeutics, detailing over 50 companies and more than 75 drugs in development. It provides an in-depth analysis of drug profiles, clinical trial stages, and therapeutic assessments, including inactive products. The report emphasizes innovations in drug mechanisms aimed at lowering intraocular pressure and improving treatment compliance. Notable emerging candidates include sepetaprost and NCX 470, highlighting advancements in ocular hypertension therapies.
Read more →OCULOcular Therapeutix Reports Fourth Quarter and Full Year 2024 Results and Business Highlights Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label fle
Ocular Therapeutix, Inc. reported its fourth quarter and full year results for 2024, highlighting key developments in its AXPAXLI program for wet AMD. The company announced an amendment to its protocol that may accelerate registration timelines while maintaining trial integrity. Despite a reported net loss of $48.4 million for Q4, financial stability is reinforced by a cash position expected to support operations into 2028. Management expressed confidence in their strategic direction and anticipated upcoming developments in non-proliferative diabetic retinopathy and diabetic macular edema treatments.
Read more →OCULOcular Therapeutix™ to Present at Two Investor Conferences in March
Ocular Therapeutix, Inc. will present at two investor conferences in March 2025, showcasing its commitment to investor engagement. The Fireside Chats will feature Dr. Pravin U. Dugel, the Executive Chairman, President, and CEO, discussing the company's vision. Alongside this, Ocular's product candidate AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration, reflecting the ongoing development of its retinal therapies.
Read more →OCULOcular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025
Ocular Therapeutix, Inc. announced a conference call scheduled for March 3, 2025, to discuss its financial results for the fourth quarter and full year ending December 31, 2024. During this call, the company aims to update stakeholders on recent business progress. Notably, its product candidate AXPAXLI is advancing through Phase 3 clinical trials for wet age-related macular degeneration. The company is also utilizing its ELUTYX technology in other products, demonstrating ongoing innovation in ocular treatments.
Read more →OCULOcular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting
Ocular Therapeutix, Inc. has announced its participation in the upcoming Angiogenesis, Exudation, and Degeneration 2025 virtual meeting scheduled for February 8, 2025. The presentations will focus on findings from their clinical trials, including OTX-TKI for neovascular AMD and its treatment for non-proliferative diabetic retinopathy. The event aims to showcase advancements in retinal therapies, highlighting both ongoing trials and the innovative science behind Ocular's product candidates.
Read more →OCULOcular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
Ocular Therapeutix has reported significant progress in its registrational trial for AXPAXLI, with 311 subjects enrolled in the SOL-R study for wet age-related macular degeneration as of January 10, 2024. The company plans to seek FDA consultation on the design of trials targeting non-proliferative diabetic retinopathy (NPDR) in the first half of 2025. Both the SOL-1 and SOL-R trials are structured to support a potential New Drug Application, with promising preliminary results from earlier studies. The overall mission is to develop sustainable treatments for these serious retinal diseases.
Read more →OCULOcular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation
Ocular Therapeutix, Inc. is set to present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. During the presentation, CEO Pravin U. Dugel will provide insights into the enrollment status of the SOL-R trial for AXPAXLI, the company's investigational therapy for wet age-related macular degeneration. The update will also cover future opportunities related to AXPAXLI and a general overview of the company's strategic direction for 2025.
Read more →OCULOcular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Ocular Therapeutix, Inc. announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco, CA. The presentation will be delivered by Pravin U. Dugel, MD, the company's Executive Chairman, President, and CEO. Ocular Therapeutix is known for its innovative therapies targeting retinal diseases, including its candidate AXPAXLI, which is in Phase 3 trials for wet age-related macular degeneration.
Read more →OCULOcular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1
Ocular Therapeutix announced that over 300 subjects have been randomized in the SOL-1 Phase 3 clinical trial for AXPAXLI, its investigational therapy for wet AMD. This marks a crucial step towards providing a durable treatment option, with topline data expected in Q4 2025. The company also began direct patient enrollment for their second registrational trial, SOL-R, reflecting strong momentum in recruitment. The trials aim to evaluate the effectiveness and safety of AXPAXLI in treating wet AMD, aligning with regulatory standards for potential new drug approval.
Read more →OCULOcular Therapeutix™ to Participate in December Investor and Scientific Conferences
Ocular Therapeutix, Inc. is set to participate in several investor and scientific conferences throughout December 2024. Key events include a fireside chat at the Piper Sandler Healthcare Conference and multiple presentations related to their ongoing clinical trials for retinal diseases. The company's product candidate, AXPAXLI, is currently in Phase 3 trials for wet age-related macular degeneration, showcasing their commitment to innovation in eye care. Their development initiatives and conference participation mark significant steps in engaging stakeholders and sharing their progress publicly.
Read more →OCULOcular Therapeutix Reports Third Quarter 2024 Results and Business Highlights SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients dire
Ocular Therapeutix reported its financial results for the third quarter of 2024, highlighting a net revenue increase driven by DEXTENZA sales. The company anticipates full randomization of the SOL-1 clinical trial by the end of 2024, with topline data expected in Q4 2025. Despite a net loss of $36.5 million this quarter, Ocular maintains a robust cash balance of $427.2 million, projected to support operations into 2028. The company is focused on advancing its Phase 3 trials for AXPAXLI while managing rising development costs.
Read more →OCULOcular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
Ocular Therapeutix, Inc. has announced its upcoming presentations at the Jefferies London Healthcare Conference and the Ophthalmology Innovation Summit XIV. These events will showcase the company's innovative approaches to treating retinal diseases, including their promising product AXPAXLI currently in Phase 3 trials. Additionally, Ocular's panel discussions will feature key topics in ophthalmology, highlighting their commitment to improving vision care.
Read more →OCULOcular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer
Ocular Therapeutix has appointed Dr. Namrata Saroj as Chief Business Officer to strengthen its leadership team. Dr. Saroj previously served as a consultant and brings over 20 years of experience in the global development and commercialization of ophthalmic drugs. She is recognized for her contributions to successful products like LUCENTIS and EYLEA. Her in-depth knowledge and connections in the retina community are expected to be key assets for Ocular's future growth, particularly in advancing their product AXPAXLI for wet age-related macular degeneration.
Read more →OCULOcular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
Ocular Therapeutix, Inc. announced plans to host a conference call on November 14, 2024, to discuss its third-quarter 2024 results. The call will cover business progress and financial outcomes for the period ending September 30, 2024. The company is focused on innovative therapies for retinal diseases, highlighting the ongoing Phase 3 clinical trials of AXPAXLI, its product candidate for wet AMD.
Read more →OCULOcular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
Ocular Therapeutix has announced accelerated timelines for their SOL-1 registrational trial of AXPAXLI in wet AMD, now expected to complete enrollment by the end of 2024, ahead of previous estimates. Topline data are projected for release in Q4 2025. The trial is conducted under a Special Protocol Agreement with the FDA, aiming to assess the efficacy of AXPAXLI in maintaining visual acuity in affected patients. The increased recruitment pace suggests heightened interest from clinical sites and potential participants.
Read more →OCULOcular Therapeutix™ to Present at October Ophthalmology Meetings
Ocular Therapeutix, Inc. announced its participation in several ophthalmology meetings taking place in Chicago during October 2024. The company will be involved in various panels, including discussions on innovation in retinal therapeutics. Notably, Ocular will present findings related to its product candidate AXPAXLI in a poster session, detailing results from a Phase 1 trial for wet age-related macular degeneration. These presentations aim to highlight the company's transition towards a focus on retinal diseases and its innovative therapy solutions.
Read more →OCULOCULAR THERAPEUTIX, INC. Amendment No. 4 to 2019 Inducement Stock Incentive Plan Ocular Therapeutix, Inc's 2019 Inducement Stock Incentive Plan (the " Plan "), pursuant to Section 11(d) thereof, is hereby amended as set
Ocular Therapeutix, Inc. has amended its 2019 Inducement Stock Incentive Plan to allow for up to 6,054,000 shares of common stock to be made available under the plan. This amendment involves a specific replacement of language in Section 4(a) of the plan. Aside from this change, all other provisions of the plan remain unchanged and in effect. The amendment was adopted by the Board of Directors on October 4.
Read more →OCULOcular Therapeutix™ to Present at the UBS Virtual Ophthalmology Day 2024
Ocular Therapeutix, a biopharmaceutical company specialized in vision-improving therapies, announced its participation in the UBS Virtual Ophthalmology Day 2024 scheduled for October 2, 2024. The event will feature a fireside chat with Dr. Pravin U. Dugel, the Executive Chairman and CEO. In addition to the chat, the company will hold investor meetings. Ocular is advancing its product candidates for retinal diseases, including AXPAXLI, which is in Phase 3 trials, and other innovative treatments leveraging its proprietary technologies.
Read more →OCULOcular Drug Delivery Technology Market Size to Reach a Valuation of USD 30.2 billion by 2034, advancing at an 5.7% CAGR | Exclusive Report by Transparency Market Research
The ocular drug delivery technology market is projected to grow substantially, reaching $30.2 billion by 2034, with a compound annual growth rate (CAGR) of 5.7% from 2024 onwards. This expansion is attributed to advancements in drug delivery technologies, including nanocarriers and MEMS devices, aimed at improving efficacy and patient compliance. With the increasing prevalence of eye conditions like diabetic retinopathy and glaucoma, the demand for innovative, non-invasive delivery systems is on the rise. The North American region, particularly the United States, is positioned as a leader in this burgeoning market due to strong research and a favorable regulatory environment.
Read more →OCULOcular Therapeutix™ to Present at September Retina Meetings
Ocular Therapeutix, Inc. announced participation in several retina meetings in September 2024 across Portugal and Spain. The company will present multiple oral presentations and panel discussions on innovative therapies for retinal diseases, including results from their Phase 1 trials. This emphasizes Ocular's ongoing development of novel treatments for conditions such as neovascular age-related macular degeneration and diabetic retinopathy. The involvement in these prominent events reflects the company's strategic focus on advancements in retinal therapies.
Read more →OCULOcular Therapeutix™ to Present at Two Investor Conferences in September
Ocular Therapeutix, Inc. has announced its participation in two upcoming investor conferences in September 2024, specifically the Baird 2024 Global Healthcare Conference and the H.C. Wainwright 26th Annual Global Investment Conference. These events will allow the company to highlight its innovative therapies for retinal diseases, including AXPAXLI, which is currently undergoing Phase 3 clinical trials for wet age-related macular degeneration. The company continues to seek ways to improve vision through its product pipeline and advanced technology.
Read more →OCULOcular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD
Ocular Therapeutix has received positive feedback from the FDA regarding its Phase 3 SOL-R clinical trial for AXPAXLI, indicating it is suitable for a New Drug Application in wet AMD. The FDA's Type C written response confirms that both the SOL-R and SOL-1 studies will support the regulatory process if completed successfully. The company is progressing well, with current trials evaluating repeat dosing and direct comparisons to current treatments like aflibercept. This regulatory clarity positions Ocular favorably in the rapidly developing landscape for wet AMD therapeutics.
Read more →OCULOcular Therapeutix Reports Second Quarter 2024 Results SOL-R AXPAXLI Repeat Dosing Study in Wet AMD Acceptable to FDA as Registrational Trial Enrollment in SOL-1 Continues to Accelerate and SOL-R Actively Enrolling Patie
Ocular Therapeutix, Inc. has reported its second-quarter 2024 financial results, highlighting continued progress in clinical trials for its lead product candidate, AXPAXLI. The FDA has deemed the SOL-R study acceptable as a registrational trial, while enrollment in the ongoing SOL-1 superiority study is accelerating. The company also announced a cash balance of $459.7 million, projected to support operations into 2028. Despite these advancements, Ocular recorded a larger net loss compared to the previous year, raising questions about financial stability as development expenses increase.
Read more →OCULOcular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024
Ocular Therapeutix, Inc. plans to report its second quarter financial results on August 7, 2024, during a scheduled conference call. The biopharmaceutical company focuses on developing innovative therapies for retinal diseases, including AXPAXLI, which is currently undergoing Phase 3 clinical trials. Additionally, Ocular has other pipeline products such as DEXTENZA and PAXTRAVA, which contribute to its portfolio of treatments for eye conditions.
Read more →OCULOcular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study
Ocular Therapeutix has announced the enrollment of the first patients in its Phase 3 SOL-R clinical trial aimed at evaluating the efficacy of AXPAXLI for treating wet age-related macular degeneration (wet AMD). This trial is a global, non-inferiority study that compares AXPAXLI's dosing regimen to the current standard of care with aflibercept. It involves approximately 825 participants and aims to provide important clinical evidence on the potential long-term treatment strategies for wet AMD. The findings from SOL-R could significantly influence practices in the retina community and improve patient outcomes in this area.
Read more →OCULOcular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
Ocular Therapeutix announced that a late-breaking abstract from its Phase 1 HELIOS study of AXPAXLI, an intravitreal implant for non-proliferative diabetic retinopathy, will be presented at the 42nd ASRS Annual Scientific Meeting. The study aims to evaluate the safety and efficacy of AXPAXLI compared to a sham control. The presentation occurs on July 18th in Stockholm, Sweden. This development signals Ocular's ongoing commitment to advancing innovative therapies for eye diseases.
Read more →OCULOcular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study
Ocular Therapeutix has reported successful enrollment in its pivotal SOL-1 study for AXPAXLI targeting wet AMD, with 151 subjects enrolled and plans for an additional repeat dosing study (SOL-R). Positive results from the 48-week HELIOS NPDR study highlight the effectiveness of AXPAXLI, with no worsening of diabetic retinopathy severity or vision-threatening complications among treated patients. The company remains on a solid financial footing, with sufficient funding anticipated to support operations through 2028. Overall, the company is making significant strides in retinal therapies.
Read more →OCULOcular Therapeutix to Host Investor Day on June 13, 2024
Ocular Therapeutix, Inc. will host an Investor Day on June 13, 2024, to outline its corporate strategy, clinical data, and development plans for AXPAXLI. The event will feature presentations from senior company leaders and retinal disease experts, discussing AXPAXLI's progress in treating wet AMD and diabetic retinopathy. It will also include KOL roundtables and a Q&A session, promoting investor engagement. Virtual access will be provided for broader participation.
Read more →OCULOcular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement grants for newly appointed Chief Medical Officer Dr. Nadia K. Waheed and six additional employees, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants include stock options and restricted stock units, with various vesting schedules tied to continued employment. This initiative underscores Ocular's commitment to enhancing its leadership team as well as advancing its biopharmaceutical developments for eye-related conditions. The company is actively involved in clinical trials for therapies targeting wet age-related macular degeneration and other ocular diseases.
Read more →OCULOcular Therapeutix Reports First Quarter 2024 Results Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI SOL-1 Phase 3 wet AMD Trial P
Ocular Therapeutix has reported its financial results for the first quarter of 2024, indicating improved revenue driven by increased sales of DEXTENZA. The company is focusing on its Phase 3 SOL-1 trial for AXPAXLI, with patient enrollment progressing as planned. Additionally, Ocular has strengthened its leadership team, which positions it for growth in retinal care. Despite a reported net loss, the company’s significant cash reserves should support its operations into 2028.
Read more →OCULOcular Therapeutix™ to Present at Two Upcoming Investor Conferences
Ocular Therapeutix, a biopharmaceutical company focused on eye diseases, has announced its participation in two upcoming investor conferences in May 2024. The conferences are the Citizens JMP Life Sciences Conference in New York and the BofA Securities 2024 Health Care Conference in Las Vegas. A live webcast of the fireside chats will be available on the company's investor website. The company continues to advance its clinical development pipeline targeting wet AMD and other eye conditions.
Read more →OCULOcular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
Ocular Therapeutix, Inc., a biopharmaceutical company focused on ocular therapies, announced it will present at the Ophthalmology Innovation Source Retina 2024 and the Association for Research in Vision and Ophthalmology 2024 meetings. The presentations will feature key findings on their investigational therapies, including AXPAXLI for retinal diseases and additional insights on drug delivery. These events are set to take place in Seattle, Washington, from May 4 to May 9, 2024, highlighting the company's commitment to advancing treatment options for vision-related conditions.
Read more →OCULOcular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
Ocular Therapeutix, Inc. has announced an Investor Day scheduled for June 13, 2024, in New York City, which will replace its first quarter earnings conference call. The company will report its first quarter 2024 financial results on May 7, 2024. This event will feature discussions on the company's corporate strategy and its pipeline for retinal diseases. Ocular specializes in developing innovative therapies for various eye conditions, including wet age-related macular degeneration and diabetic retinopathy.
Read more →OCULOcular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
Ocular Therapeutix announced promising topline results from its Phase 1 HELIOS study for AXPAXLI, showing that 46.2% of participants had a 1- or 2-step improvement in diabetic retinopathy at 40 weeks. The treatment was well tolerated, with no cases of inflammation or worsening of the condition in the treatment group. Ocular is now preparing to progress to Phase 3 trials for AXPAXLI, pending discussions with the FDA, having observed durable effects from a single injection. These findings suggest a significant potential for AXPAXLI in treating diabetic retinopathy.
Read more →OCULOCULAR THERAPEUTIX, INC. Amendment No. 3 to 2019 Inducement Stock Incentive Plan Ocular Therapeutix, Inc's 2019 Inducement Stock Incentive Plan (the " Plan "), pursuant to Section 11(d) thereof, is hereby amended as set
Ocular Therapeutix, Inc. has announced an amendment to its 2019 Inducement Stock Incentive Plan, increasing the number of shares available for awards to 4,804,000. This change was made in accordance with Section 11(d) of the Plan. Apart from this specific amendment, all other terms of the Plan remain unchanged and effective. The Board of Directors adopted this amendment on April 16.
Read more →OCULOcular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Ocular Therapeutix has announced key appointments to strengthen its clinical development team, including Nadia K. Waheed as Chief Medical Officer and Peter K. Kaiser as Chief Development Officer. These leaders bring extensive experience in retinal diseases, particularly in advancing the AXPAXLI program targeting wet age-related macular degeneration and diabetic retinopathy. The appointments are set to take effect from May 20, 2024, and are aimed at enhancing Ocular's position in retinal care. The strengthened team is expected to significantly contribute to the clinical execution of their innovative therapies.
Read more →OCULOcular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
Ocular Therapeutix, Inc. has announced a leadership change with Dr. Pravin U. Dugel stepping up as President and CEO, while Antony Mattessich resigns from the position effective immediately. Dr. Dugel, who will continue to serve as Executive Chairman, expressed gratitude for Mattessich's service and emphasized the potential of AXPAXLI, the company's innovative product for retinal disease. This transition occurs as Ocular advances its clinical programs, particularly for wet age-related macular degeneration. Mattessich conveyed confidence in Dugel's capability to lead the company in its next phase.
Read more →OCULOcular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
Ocular Therapeutix, Inc. has announced the granting of inducement equity awards to Liansheng Zhu, its new Senior Vice President and Global Head of Biometrics, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards include a non-statutory stock option for 130,000 shares and a restricted stock unit award for 43,333 shares, both subject to vesting conditions over several years. This move indicates Ocular Therapeutix's strategy to strengthen its executive team and possibly enhance its operational capabilities in developing therapies for eye diseases.
Read more →OCULOcular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Ocular Therapeutix reported positive Phase 2 results for PAXTRAVA, its intravitreal implant for treating open-angle glaucoma, at the ASCRS Annual Meeting. The study demonstrated significant and sustained reductions in Intraocular Pressure (IOP) for up to six months, where 81.3% of patients did not require additional therapy. The data highlighted the implant's safety profile, revealing no adverse effects on corneal health. The next steps include discussions with the FDA to move towards Phase 3 trials and further development of their retinal disease portfolio.
Read more →OCULOcular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
Ocular Therapeutix, Inc. has announced its participation at the 2024 ASCRS Annual Meeting, where it will present multiple research findings related to eye diseases. Among the topics, the company will showcase the results of phase trials for their products targeting open-angle glaucoma and the safety of intracanlicular dexamethasone applications in cataract surgery. This opportunity highlights their ongoing commitment to advancing treatment options and improving the quality of life for patients with ocular conditions. The meeting will take place from April 5-8, 2024, in Boston, Massachusetts.
Read more →OCULOcular Inflammation Treatment Market InsightAce Exclusive Report 2024-2031
The Global Ocular Inflammation Treatment Market is projected to grow significantly, from US$ 428.7 million in 2023 to US$ 690.4 million by 2031, with a CAGR of 6.31%. Factors such as an aging population and increased environmental issues are contributing to this demand. However, challenges remain, including high drug costs and a lack of trained professionals in emerging markets. Recent FDA approvals of innovative treatments further enhance market prospects.
Read more →OCULOcular Therapeutix Reports Fourth Quarter and Full Year 2023 Results Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI Phase 3 SOL-1 Trial for Wet AMD Topline Clinic
Ocular Therapeutix, Inc. has released its financial results for the fourth quarter and full year of 2023, showcasing an increase in revenue and significant funding raised through private placement. The company is focused on advancing its clinical program for AXPAXLI, its treatment for wet AMD, and has announced upcoming milestones and a leadership restructuring. Despite reporting net losses, Ocular's strong cash position and ongoing clinical trials signal positive potential in retinal care advancements. An Investor Day is planned for Q2 2024 to outline the updated corporate strategy.
Read more →OCULOcular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
Ocular Therapeutix, Inc. announced that it will release its fourth quarter and full year 2023 financial results on March 11, 2024. The company has decided not to host a conference call following these results due to recent leadership changes and a successful $325 million private placement. A conference call discussing corporate strategy is planned for the second quarter of 2024. Ocular's innovative pipeline includes AXPAXLI for wet AMD and PAXTRAVA for primary open-angle glaucoma, reflecting their commitment to enhancing vision and life quality.
Read more →OCULOcular Therapeutix™ Announces Board of Directors and Leadership Updates
Ocular Therapeutix announced significant leadership updates, including the appointment of Pravin U. Dugel, MD, as Executive Chair and other key figures to pivotal roles. This transition is aimed at enhancing their operations in retina care, particularly for the AXPAXLI™ Phase 3 wet AMD programs. The expanded leadership brings extensive expertise, which the company believes will facilitate accelerated development and potentially transform treatments for retinal diseases. Existing board members have transitioned roles to accommodate these changes, fostering an energized approach for Ocular's future in the ophthalmology market.
Read more →OCULOcular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
Ocular Therapeutix, Inc. announced inducement equity awards to its newly appointed Executive Chairman, Pravin U. Dugel, MD, and Chief Strategy Officer, Sanjay Nayak, MBBS, PhD. These awards were approved by the Compensation Committee and aim to incentivize the new leaders under Nasdaq Listing Rule 5635(c)(4). Dr. Dugel's package includes a stock option for 1,282,469 shares while Dr. Nayak will receive options for 244,550 shares. This move is expected to support Ocular's commitment to developing therapies for ocular diseases.
Read more →OCULOcular Therapeutix, Inc. Announces $325.0 Million Private Placement BEDFORD, MA
Ocular Therapeutix, Inc. announced a private placement worth approximately $325 million, aimed at accelerating the development of its therapies for eye diseases. The placement involves the sale of common stock and pre-funded warrants to both new and existing investors. The funds will specifically support ongoing pivotal Phase 3 trials for AXPAXLI, which targets wet age-related macular degeneration (AMD), alongside other clinical initiatives. The closing of this placement is anticipated by February 26, 2024, subject to standard conditions.
Read more →OCULOcular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
Ocular Therapeutix, Inc. has appointed Steve Meyers as the new Chief Commercial Officer, recognizing his leadership and strategic vision. Meyers brings over 20 years of experience in commercial roles within biotechnology, aiming to enhance the company's focus on innovative eye therapies. His previous experience includes significant positions at Regeneron and AbbVie. The company is focused on advancing its drug portfolio to improve patient quality of life amidst various commercial and regulatory challenges.
Read more →OCULOcular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
Ocular Therapeutix announced that the first subjects have been screened in the Phase 3 SOL-1 clinical trial for AXPAXLI, aimed at treating wet AMD. AXPAXLI, an investigational intravitreal implant, has shown promising preliminary results, suggesting it could reduce the frequency of necessary injections for patients. This marks a pivotal step in the company's efforts to develop a new therapy that could improve patient outcomes in managing wet AMD. The trial follows an agreement with the FDA on a Special Protocol Assessment, further validating the study's design.
Read more →OCULOcular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
Ocular Therapeutix has announced a modification to its Special Protocol Assessment (SPA) for the pivotal Phase 3 SOL clinical trial of AXPAXLI for wet AMD, approved by the FDA. The amendment broadens the eligibility criteria, potentially accelerating trial enrollment by allowing treatment-naïve participants with better visual acuity. The new trial configuration is designed to enhance drug release and synchronization with hydrogel bioresorption. This change is expected to facilitate better engagement with clinical sites and improve patient outcomes.
Read more →OCULOcular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Ocular Therapeutix, Inc. announced the closing of its public offering of 35,420,000 shares of common stock priced at $3.25 per share, resulting in gross proceeds of approximately $115.1 million. This offering included additional shares purchased by the underwriters. The company intends to utilize the proceeds to fund the Phase 3 clinical development of AXPAXLI for wet AMD, as well as to support other clinical programs and general corporate purposes. The offering was executed under a previously effective shelf registration with the SEC.
Read more →OCULOcular Therapeutix™ Announces Pricing of Public Offering of Common Stock
Ocular Therapeutix announced a public offering of 30,800,000 shares of its common stock priced at $3.25 per share, aiming to raise gross proceeds of approximately $100.1 million. The funds will primarily support the Phase 3 clinical development of AXPAXLI for the treatment of wet AMD, including ongoing and planned trials. The public offering is expected to close on or about December 18, 2023, contingent on customary closing conditions, and involves a 30-day option for underwriters to purchase additional shares.
Read more →OCULOcular Therapeutix TM Announces Pricing of Public Offering of Common Stock
Ocular Therapeutix, Inc. announced the pricing of an underwritten public offering of 30,800,000 shares of common stock at $3.25 per share, expected to raise gross proceeds of $100.1 million. The offering, which includes an additional option for underwriters to purchase more shares, is set to close around December 18, 2023. Proceeds are intended to fund the Phase 3 development of AXPAXLI for wet AMD and other clinical development programs. The offering is conducted under a previously effective shelf registration statement with the SEC.
Read more →OCULOcular Therapeutix™ Announces Proposed Public Offering of Common Stock
Ocular Therapeutix announced a proposed underwritten public offering of its common stock aimed at financing the development of its treatments. The company plans to utilize net proceeds to fund the Phase 3 clinical trial of AXPAXLI for wet AMD and other clinical programs. The offering is contingent upon market conditions, and the company has granted underwriters a 30-day option to purchase additional shares. Jefferies, BofA Securities, and Piper Sandler are the joint book-running managers for the offering.
Read more →OCULOcular Therapeutix™ to Present at Three Upcoming Investor Conferences
Ocular Therapeutix, Inc. will participate in three upcoming investor conferences, including the Jefferies London Healthcare Conference, BTIG 3rd Annual Ophthalmology Day, and Piper Sandler 35th Annual Healthcare Conference. Company management will be available throughout the conferences for investor meetings. The events will feature fireside chats where the company will discuss its innovative treatments and technologies in ophthalmology. These presentations aim to improve investor relations and highlight ongoing clinical development efforts in eye-related therapies.
Read more →OCULOcular Therapeutix Provides Third Quarter 2023 Financial Results and Corporate Update FDA Agrees to Overall Design of the First Pivotal Trial for AXPAXLI in Wet AMD under a Special Protocol Assessment; Expect First Subje
Ocular Therapeutix has reported its financial results for Q3 2023, highlighting a 26% revenue increase year-over-year, totaling $15.1 million. The FDA has approved the overall design of the pivotal trial for AXPAXLI aimed at treating wet AMD, with first dosing expected by year-end. In addition, the company anticipates presenting top-line data from the HELIOS trial for diabetic retinopathy in Q2 2024. Despite positive revenue growth, the company posted a net loss of $(0.5) million, driven by higher clinical trial expenses.
Read more →OCULOcular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
Ocular Therapeutix has announced receiving FDA agreement under a Special Protocol Assessment for its pivotal Phase 3 trial of AXPAXLI, an investigational treatment for wet age-related macular degeneration. The company aims to enroll around 300 patients in the trial, which began in September 2023, and expects to dose the first subject by year-end. AXPAXLI is designed as a bioresorbable implant that could offer an innovative solution for treating wet AMD, addressing challenges associated with current therapies.
Read more →OCULOcular Therapeutix™ To Report Third Quarter 2023 Financial Results
Ocular Therapeutix, Inc. announced that it will report its financial results for the third quarter ended September 30, 2023, after the market close on November 7, 2023. Following the release, the management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a general business update. The company is engaged in developing innovative therapies for eye diseases and has several products in various stages of clinical trials.
Read more →OCULTransformative Investigational Tyrosine Kinase Inhibitor Therapy for Retinal Vascular Diseases OCULAR THERAPEUTIX (NASDAQ: OCUL) Antony Mattessich President & Chief Executive Officer EURETINA Innovation Spotlight 4 th Oc
Ocular Therapeutix is advancing its investigational therapy OTX-TKI for retinal vascular diseases, particularly wet AMD. This therapy combines axitinib with the Elutyx technology for continuous drug delivery, potentially reducing treatment burden significantly. Initial data indicates that patients could experience an 89% reduction in anti-VEGF treatment requirements over 12 months. However, the company faces various risks, including regulatory uncertainties and the need for further clinical validation of its approach.
Read more →OCULOcular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
Ocular Therapeutix has initiated its first pivotal clinical trial for OTX-TKI, an axitinib intravitreal implant aimed at treating wet age-related macular degeneration (AMD). The trial will evaluate approximately 300 naive patients, comparing OTX-TKI to established treatments like aflibercept. Preliminary results from a Phase 1 trial indicated significant reductions in treatment burden while maintaining visual acuity. The involvement of prominent retinal specialists suggests a robust framework for the trial, as the company aims to address a pressing need in wet AMD treatment.
Read more →OCULOcular Hypertension Treatment Global Market Report 2023
The global ocular hypertension treatment market is anticipated to increase from $4.94 billion in 2022 to $5.14 billion in 2023, driven by a compound annual growth rate of 4.03%. Factors contributing to this growth include the rising prevalence of glaucoma, which is expected to affect over 111 million individuals by 2040. Additionally, product innovation is pivotal, with companies like Alcon and Sandoz launching new solutions and expanding their portfolios through acquisitions. The market report outlines various treatments and the regional distribution of the market.
Read more →OCULOcular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Ocular Therapeutix, Inc. has announced that their CEO, Antony Mattessich, will participate in a panel at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference on August 16, 2023. The management team will also host investor meetings during the conference to foster engagement. This event provides a platform for Ocular Therapeutix to showcase their innovative ocular therapies. Investors can access a live webcast of the panel through the company's website.
Read more →OCULOcular Therapeutix Provides Second Quarter 2023 Financial Results and Corporate Update DEXTENZA Net Product Revenue in Q2 2023 was $15.0 million, Representing Growth of Approximately 24% Over Q2 2022 Closed on a New $82.
Ocular Therapeutix reported strong financial results for Q2 2023, showcasing a 24% increase in net product revenue, reaching $15 million. The company also secured an $82.5 million credit facility, extending its cash runway into 2025. Pivotal trials for the treatment of wet AMD are set to begin in Q3 2023, marking significant progress in their ophthalmology pipeline. However, it also reported a net loss of $20.7 million for the quarter, reflecting rising operating costs.
Read more →OCULOcular Therapeutix™ To Report Second Quarter 2023 Financial Results
Ocular Therapeutix, Inc. announced its plan to report financial results for the second quarter of 2023 on August 7, 2023, after the market close. The management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss these results and offer a business update. Investors and analysts are encouraged to register for the webcast ahead of time, and a replay will be accessible for 90 days post-event.
Read more →OCULOcular Therapeutix™ Announces Appointment of New Board Member
Ocular Therapeutix, Inc. has announced the appointment of Adrienne L. Graves, Ph.D., to its Board of Directors. Dr. Graves, a seasoned leader in ophthalmology, previously served as CEO of Santen Inc. and has vast experience in clinical development and commercialization within the industry. The company anticipates benefiting from her insights and expertise to enhance its growth and advance its product pipeline. Dr. Graves has held significant roles in various organizations and is recognized for her contributions to ophthalmology.
Read more →OCULMonth 10 Analysis (Presented at Angiogenesis 2023) Month 7 Analysis (Presented at AAO 2022) 1 OTX - TKI U.S. - based Wet AMD Clinical Trial Design OTX - TKI Arm Aflibercept Arm OTX - TKI 600 g single implant injection Af
The analysis presented at Angiogenesis 2023 highlighted the performance of OTX-TKI in a clinical trial for treating wet age-related macular degeneration (AMD). The study demonstrated significant reductions in treatment burden compared to traditional therapies, with a noteworthy 60% of patients remaining rescue-free at 12 months. While the OTX-TKI showed comparable improvements in vision and central subfield thickness to Aflibercept, safety concerns arose with reports of adverse events such as acute endophthalmitis and elevated intraocular pressure. The findings suggest promising outcomes for OTX-TKI, emphasizing its potential to enhance patient care in wet AMD.
Read more →OCULOcular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD
Ocular Therapeutix has announced 12-month topline data from its Phase 1 clinical trial of OTX-TKI for wet AMD. The investigational implant demonstrated sustained visual outcomes comparable to aflibercept while significantly reducing treatment burden. Importantly, no serious adverse events were noted throughout the study period. However, the data indicated that some subjects required additional rescue therapy by Month 12, suggesting a re-dosing timeline due to declining effectiveness.
Read more →OCULOcular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy
Ocular Therapeutix has completed enrollment in the HELIOS clinical trial for their investigational therapy OTX-TKI, designed to treat diabetic retinopathy and wet AMD. The trial aims to validate the efficacy of OTX-TKI, an axitinib intravitreal implant, against a sham injection. Interim data is anticipated in early 2024, with potential plans to initiate a pivotal Phase 3 trial contingent upon favorable results and funding. The advancement of OTX-TKI could potentially change the treatment paradigm for diabetic retinopathy.
Read more →OCULOcular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting
Ocular Therapeutix announced it will present 12-month top-line data from its U.S.-based Phase 1 clinical trial of OTX-TKI for wet age-related macular degeneration at the 2023 Clinical Trials at the Summit Annual Meeting. The data is expected to show promising results, including a significant reduction in treatment burden. A conference call is scheduled following the presentation to discuss the findings in detail. This event will also feature a panel discussion on challenges in introducing novel treatments to the market.
Read more →OCULOcular Therapeutix™ to Present at the Jefferies Global Healthcare Conference
Ocular Therapeutix, Inc. announced its participation in the Jefferies Global Healthcare Conference on June 8, 2023, where CEO Antony Mattessich will engage in a fireside chat. The management team will also host investor meetings, encouraging participation from interested investors through their Jefferies representatives. This event aims to enhance the company's visibility and investor relations. Furthermore, Ocular Therapeutix specializes in innovative therapies for eye conditions, showcasing its commitment to advancing ocular health.
Read more →OCULOcular Therapeutix™ to Present at the JMP Securities Life Sciences Conference
Ocular Therapeutix, Inc. will participate in the JMP Securities Life Sciences Conference on May 15, 2023, where CEO Antony Mattessich will lead a fireside chat. The company will also host investor meetings, providing opportunities for direct engagement with management. Attendees can access a live webcast of the event through the Investors section of Ocular Therapeutix's website. The company focuses on innovative therapies for eye diseases, with several products in development and one FDA-approved treatment, DEXTENZA.
Read more →OCULOcular Therapeutix Provides First Quarter 2023 Financial Results and Corporate Update 12-month Top-Line Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet
Ocular Therapeutix has announced its financial results for the first quarter of 2023, reporting a net product revenue of $13.2 million, which shows a 6% increase over the previous year. The company is set to present important 12-month data on its Phase 1 clinical trial for OTX-TKI, targeting wet AMD, at the upcoming Clinical Trials at the Summit meeting. However, the company also faced a significant rise in net loss compared to the same quarter last year, contributing to ongoing financial challenges. The management remains optimistic about further advancements in their pipeline and positive interactions with the FDA regarding future treatments.
Read more →OCULOcular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Ocular Therapeutix, Inc. announced the presentation of multiple scientific data at the 2023 ASCRS Annual Meeting, focusing on their product DEXTENZA. The presentations will emphasize the efficacy of DEXTENZA in improving compliance and managing self-administration of eye drops in patients. Key topics include comparisons of hydrogel-based insertion techniques and trials for treating ocular conditions. The event is set to take place in San Diego, California from May 5-8, 2023.
Read more →OCULOcular Therapeutix™ To Report First Quarter 2023 Financial Results
Ocular Therapeutix, Inc. is set to report its first quarter financial results for 2023 on May 8, 2023, after market close. The announcement includes a live conference call and webcast to discuss the results and offer a business update. The company is known for its innovative therapies targeting diseases of the eye and has several products in various stages of development, including FDA-approved treatments and ongoing clinical trials.
Read more →OCULOcular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Ocular Therapeutix, Inc. has announced that it will be presenting several pre-clinical and clinical data at the upcoming ARVO Annual Meeting in New Orleans. Presentations will include updates on various drug candidates, such as OTX-TKI for neovascular AMD and OTX-TIC for glaucoma. The company expresses optimism about its hydrogel technology's ability to enhance effectiveness while reducing treatment burdens. Overall, these presentations highlight the ongoing development of their innovative therapies aimed at improving eye health.
Read more →OCULOcular Therapeutix Provides Fourth Quarter and Year-End 2022 Results and Corporate Update Presented Positive 10-month Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for
Ocular Therapeutix announced its fourth quarter and year-end 2022 financial results, showcasing 18% revenue growth and a net revenue of $51.5 million. The company presented positive interim data from the Phase 1 trial of OTX-TKI, an implant for wet AMD, at a recent conference. Furthermore, Ocular initiated a Phase 1 trial for OTX-TKI for diabetic retinopathy. However, the company reported substantial losses, amounting to $(71.0) million for the full year, raising concerns about its financial health amid growing revenues.
Read more →OCULOcular Therapeutix™ to Present at Cowen’s 43rd Annual Healthcare Conference
Ocular Therapeutix, Inc. announced that its CEO, Antony Mattessich, will participate in a fireside chat at Cowen’s 43rd Annual Healthcare Conference on March 7, 2023. The company will also host investor meetings during the conference, emphasizing its commitment to investor relations. Ocular Therapeutix specializes in developing innovative therapies for eye conditions, with several drugs in different stages of clinical trials. The presentation will be accessible through a live webcast.
Read more →OCULOcular Therapeutix™ To Report Fourth Quarter and Year-End 2022 Financial Results
Ocular Therapeutix, Inc. announced the upcoming release of its fourth quarter and year-end financial results set to occur after the market close on March 6, 2023. Following the earnings announcement, the management team will host a live conference call and webcast to discuss financial performance and business updates. The company, which specializes in eye disease treatments, currently has several products in various stages of clinical development.
Read more →OCULOcular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD
Ocular Therapeutix announced promising interim data from its Phase 1 clinical trial evaluating OTX-TKI for treating wet AMD. The data revealed a 73% rescue-free rate among subjects up to Month 10, with similar efficacy to aflibercept. OTX-TKI demonstrated good tolerability with no serious drug-related adverse events. The company plans to discuss future clinical requirements with the FDA and aims to initiate a pivotal trial in the third quarter of 2023, subject to financing.
Read more →OCULOcular Therapeutix Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones Dextenza Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over
Ocular Therapeutix provided a corporate update detailing the growth in Dextenza revenue, estimating $13.6 million for Q4 2022, a 14% increase. Overall, 2022 revenue reached approximately $50.2 million, marking a 20% growth from the previous year. The company is making strides in clinical trials with OTX-TKI, applying for wet AMD and diabetic retinopathy treatments, and is set to present data at the Angiogenesis Conference. Additional results from its ongoing studies, including OTX-TIC for glaucoma, are expected later in 2023.
Read more →OCULOcular Therapeutix Reports Third Quarter 2022 Financial Results and Business Update Announced Positive Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD at the American Acade
Ocular Therapeutix Reports Third Quarter 2022 Financial Results and Business Update Announced Positive Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting Initiation
Read more →OCULOcular Therapeutix Reports Second Quarter 2022 Financial Results and Business Update Interim Data from the U.S.-based Clinical Trial for OTX-TKI for the Treatment of Wet AMD to be Presented at American Academy of Ophthal
Ocular Therapeutix Reports Second Quarter 2022 Financial Results and Business Update Interim Data from the U.S.-based Clinical Trial for OTX-TKI for the Treatment of Wet AMD to be Presented at American Academy of Ophthalmology (AAO) in the Third Quarter of 2022 (dexamethasone
Read more →OCULOcular Therapeutix Reports First Quarter 2022 Financial Results and Business Update DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg Recorded Quarterly Net Product Revenue of $12.5 Million, Representing Year-Over-Year G
Ocular Therapeutix Reports First Quarter 2022 Financial Results and Business Update (dexamethasone ophthalmic insert) 0.4 mg Recorded Quarterly Net Product Revenue of $12.5 Million, Representing Year-Over-Year Guiding DEXTENZA Annual Net Product Revenue for 2022 between $55 t
Read more →OCULOcular Therapeutix Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg Recorded Net Quarterly Sales of $12.2 Million, Representing Year-Over-Ye
Ocular Therapeutix Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update (dexamethasone ophthalmic insert) 0.4 mg Recorded Net Quarterly Sales of $12.2 Million, Representing Year-Over-Year Creating New Business Unit Focused on Optimizing the Commercia
Read more →OCULOcular Therapeutix Reports Third Quarter 2021 Financial Results and Business Update DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg Recorded Net Quarterly Sales of $11.9 Million, Representing Year-Over-Year Growth of 1
Ocular Therapeutix Reports Third Quarter 2021 Financial Results and Business Update DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg Recorded Net Quarterly Sales of $11.9 Million, Representing Year-Over-Year Growth of 120% FDA Approved Supplemental New Drug Application (sND
Read more →OCULOcular Therapeutix Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million Company Anticipates Record Quarter for In-Market DEXTENZA Sales Second Quarter 2021 Net Product Revenue Up Approximately 6
Therapeutix Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million Anticipates Record Quarter for In-Market DEXTENZA Sales Quarter 2021 Net Product Revenue Up Approximately 60% and In-Market Unit Volumes Up Approximately 50% Sequentially Over the First Q
Read more →OCULOcular Therapeutix Reports Second Quarter 2021 Financial Results and Business Update DEXTENZA Recorded Net Quarterly Sales of $11.1 Million, Representing Quarterly Sequential Growth of Approximately 65% Initiated First C
Ocular Therapeutix Reports Second Quarter 2021 Financial Results and Business Update DEXTENZA Recorded Net Quarterly Sales of $11.1 Million, Representing Quarterly Sequential Growth of Approximately 65% Initiated First Clinical Trial in the U.S. to Assess a Single OTX-TKI Im
Read more →OCULOcular Therapeutix Reports First Quarter 2021 Financial Results and Business Update DEXTENZA Achieved Quarterly Record of 16,634 Billable Units Sold to End Customers, Representing Quarterly Sequential Growth of 15%. BEDF
Ocular Therapeutix Reports First Quarter 2021 Financial Results and Business Update Achieved Quarterly Record of 16,634 Billable Units Sold to End Customers, Representing Quarterly Sequential Mass.--(BUSINESS WIRE)- May 5, 2021 -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a bio
Read more →OCULOcular Therapeutix Reports Fourth Quarter and Year End 2020 Financial Results and Business Update BEDFORD, Mass.--(BUSINESS WIRE)- March 11 , 2021 -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company fo
Ocular Therapeutix Reports Fourth Quarter and Year End 2020 Financial Results and Business Update BEDFORD, Mass.--(BUSINESS WIRE)- March 11, 2021 -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercializat
Read more →OCULCohort 1: n=6 until Month 9; Cohort 2: n=7 until Month 9; n=6 for Month 11; n=6 for Month 12; n=4 for Month 14 Cohort 3a: n=5 until Month 1; n=3 for Month 2; n=2 for Month 3; n=1 for Month 4.5 & 6; Cohort 3b: n=2 until M
Cohort 1: n=6 until Month 9; Cohort 2: n=7 until Month 9; n=6 for Month 11; n=6 for Month 12; n=4 for Month 14 Cohort 3a: n=5 until Month 1; n=3 for Month 2; n=2 for Month 3; n=1 for Month 4.5 & 6; Cohort 3b: n=2 until Month 2; n=1 unti l M onth 3 *All BCVA and CSFT values compar
Read more →OCULOTX - TIC, AN INTRACAMERAL HYDROGEL - BASED TRAVOPROST IMPLANT TO TREAT PATIENTS WITH GLAUCOMA & OCULAR HYPERTENSION PHASE 1 TRIAL UPDATE MICHAEL GOLDSTEIN, MD, MBA PRESIDENT, OPHTHALMOLOGY & CHIEF MEDICAL OFFICER GLAUCO
OTX - TIC, AN INTRACAMERAL HYDROGEL - BASED TRAVOPROST IMPLANT TO TREAT PATIENTS WITH GLAUCOMA & OCULAR HYPERTENSION PHASE 1 TRIAL UPDATE MICHAEL GOLDSTEIN, MD, MBA PRESIDENT, OPHTHALMOLOGY & CHIEF MEDICAL OFFICER GLAUCOMA 360 | VIRTUAL | JANUARY , 2021 (NASDAQ: OCUL) FINANCIAL
Read more →OCULTRANSFORMING DRUG DELIVERY LEVERAGING A NOVEL TECHNOLOGY PLATFORM (NASDAQ: OCUL) ANTONY MATTESSICH, CHIEF EXECUTIVE OFFICER January 2021 FORWARD LOOKING STATEMENTS 2 Any statements in this presentation about future expec
TRANSFORMING DRUG DELIVERY LEVERAGING A NOVEL TECHNOLOGY PLATFORM (NASDAQ: OCUL) ANTONY MATTESSICH, CHIEF EXECUTIVE OFFICER January 2021 FORWARD LOOKING STATEMENTS 2 Any statements in this presentation about future expectations, plans, and prospects for the Company, including th
Read more →OCULOcular Therapeutix Announces Proposed Public Offering of Common Stock
Ocular Therapeutix Announces Proposed Public Offering of Common Stock BEDFORD, Mass, December 14, 2020 - Ocular Therapeutix , Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases a
Read more →OCULOcular Therapeutix Reports Third Quarter 2020 Financial Results and Business Update October Financing Raised $75.2 Million in Proceeds Net of Fees DEXTENZA Net Product Revenue in Third Quarter of $5.4 Million, a 280% Inc
Ocular Therapeutix Reports Third Quarter 2020 Financial Results and Business Update Raised $75.2 Million in Proceeds Net of Fees Net Product Revenue in Third Quarter of $5.4 Million, a 280% Increase from the Prior Quarter Phase 1 Results and Recently Initiated Phase 2 Clinica
Read more →OCULOcular Therapeutix Announces Preliminary Net Product Revenue of $5.8 Million to $5.9 Million for Third Quarter 2020, Representing Greater Than a 250% Increase Over the Previous Quarter BEDFORD, MASS. - (BUSINESS WIRE)
Ocular Therapeutix Announces Preliminary Net Product Revenue of $5.8 Million to $5.9 Million for Third Quarter 2020, Representing Greater Than a 250% Increase Over the - (BUSINESS WIRE) - October 7, 2020 - Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company foc
Read more →OCULOcular Therapeutix Reports Second Quarter 2020 Financial Results and Business Update Newly Published Physician Fee Schedules for 0356T for the Administration of Intracanalicular Inserts to Support Ongoing DEXTENZA Launch
Ocular Therapeutix Reports Second Quarter 2020 Financial Results and Business Update Newly Published Physician Fee Schedules for 0356T for the Administration of Intracanalicular Inserts to Support Ongoing DEXTENZA Launch May Financing Yields $48.3 Million in DEXTENZA Net Pro
Read more →OCULOcular Therapeutix Presents at the 12 th Annual Ophthalmology Innovation Summit (OIS) DEXTENZA Sets Billable Insert In-Market Sales Record in June and Company Announces Preliminary Second Quarter 2020 Net Product Revenue
Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS) Sets Billable Insert In-Market Sales Record in June and Company Announces Preliminary Second Quarter 2020 MASS. - (BUSINESS WIRE) - July 17, 2020 - Ocular Therapeutix, Inc. (NASDAQ: OCUL), a b
Read more →OCUL(NASDAQ: OCUL) TRANSFORMING DRUG DELIVERY LEVERAGING A NOVEL TECHNOLOGY PLATFORM ANTONY MATTESSICH, CHIEF EXECUTIVE OFFICER Ophthalmology Innovation Summit (OIS) Virtual Public Company Showcase
Our market opportunity for such indications reflects a portion of this market. * In collaboration with REGENERON; Data shown here is only representative of Dry Eye and not other Ocular Surface Diseases 1. 2019 Retina Pharma Market Scope Report 2. 2019 Glaucoma Pharma Market Scope
Read more →OCULOcular Therapeutix Reports First Quarter 2020 Financial Results and Business Update Presented Interim Clinical Data for OTX-TKI Showing Favorable Safety Profile, Tolerability, Durability and Early Biological Activity Ann
Ocular Therapeutix Reports First Quarter 2020 Financial Results and Business Update Presented Interim Clinical Data for OTX-TKI Showing Favorable Safety Profile, Tolerability, Durability and Early Biological Activity Announced Positive Phase 3 Clinical Trial for DEXTENZA in
Read more →OCULOcular Therapeutix Provides Business Update and Response to COVID-19 Global Pandemic BEDFORD, Mass. -(BUSINESS WIRE)
Ocular Therapeutix Provides Business Update and Response to COVID-19 Global Pandemic BEDFORD, Mass. -(BUSINESS WIRE)-April 13, 2020-Ocular Therapeutix , Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovati
Read more →OCULOcular Therapeutix Reports Fourth Quarter and Year End 2019 Financial Results and Business Update Fourth Quarter DEXTENZA Net Product Revenue of $1.6 million, a 433% Sequential Increase; Guiding First Quarter Total Net P
Ocular Therapeutix Reports Fourth Quarter and Year End 2019 Financial Results and Business Update Fourth Quarter DEXTENZA Net Product Revenue of $1.6 million, a 433% Sequential Increase; Guiding First Quarter Total Net Product Revenue of $3.0 million to $3.2 million Presented
Read more →OCULOcular Therapeutix Announces Preliminary Fourth Quarter 2019 Net Product Revenue and Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial at the Cowen 40 th Annual Health Care Conference BEDFORD, Mass.
Announces Preliminary Fourth Quarter 2019 Net Product Revenue and Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial at the Cowen 40th Annual Health Care Conference BEDFORD, Mass. -(BUSINESS WIRE)-March 3, 2020-Ocular Therapeutix , Inc. (NASDAQ: OCUL), a b
Read more →OCULIf the study eye was given other IOP lowering medication, the IOP value was removed from the analysis. COHORT 1: MEAN IOP CHANGE FROM BASELINE NB: Interim look; Unmonitored data. For consistency, reflects only IOP data c
*If the study eye was given other IOP lowering medication, the IOP value was removed from the analysis. COHORT 1: MEAN IOP CHANGE FROM BASELINE NB: Interim look; Unmonitored data. For consistency, reflects only IOP data collected at 8 a.m. timepoint and excludes additional data c
Read more →OCULOcular Therapeutix Reports Third Quarter 2019 Financial Results and Business Update Over 7,000 Patients Treated Since Launch at more than 350 Surgical Sites Expanded the DEXTENZA Field Team by 50% Implemented Restructuri
Ocular Therapeutix Reports Third Quarter 2019 Financial Results and Business Update Over 7,000 Patients Treated Since Launch at more than 350 Surgical Sites Expanded the DEXTENZA Field Team by 50% Implemented Restructuring Plan That Extends Cash Runway Through the Fourth Quart
Read more →OCULOcular Therapeutix Reports Second Quarter 2019 Financial Results and Business Update Commenced U.S. Launch of DEXTENZA with Broad Reimbursement Status and Differentiated Product Label BEDFORD, Mass. (BUSINESS WIRE)
Ocular Therapeutix Reports Second Quarter 2019 Financial Results and Business Update Commenced U.S. Launch of DEXTENZA with Broad Reimbursement Status and Differentiated Product Label BEDFORD, Mass. (BUSINESS WIRE) August 7, 2019 Ocular Therapeutix , Inc. (NASDAQ: OCUL), a biop
Read more →OCULOTX-TP PHASE 3 TRIAL: Topline Efficacy results Mean intraocular pressure Diurnal Timepoints 2 Weeks 6 Weeks 12 Weeks OTX-TP mm Hg Placebo mm Hg LS Mean P-value OTX-TP mm Hg Placebo mm Hg LS Mean P-value OTX-TP mm Hg Plac
OTX-TP PHASE 3 TRIAL: Topline Efficacy results Mean intraocular pressure Diurnal Timepoints 2 Weeks 6 Weeks 12 Weeks OTX-TP mm Hg Placebo mm Hg LS Mean P-value OTX-TP mm Hg Placebo mm Hg LS Mean P-value OTX-TP mm Hg Placebo mm Hg LS Mean P-value 8:00 AM 21.02 22.86 <.0001 21.93 2
Read more →OCULOcular Therapeutix Reports First Quarter 2019 Financial Results and Business Update DEXTENZA Commercial Launch Scheduled for Mid-Year 2019 BEDFORD, Mass. (BUSINESS WIRE)
Ocular Therapeutix Reports First Quarter 2019 Financial Results and Business Update DEXTENZA Commercial Launch Scheduled for Mid-Year 2019 BEDFORD, Mass. (BUSINESS WIRE) March 10, 2019 Ocular Therapeutix , Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulat
Read more →OCULOcular Therapeutix, Inc. Settles Litigation with Mati Therapeutics, Inc. BEDFORD, MASS. (BUSINESS WIRE)
Ocular Therapeutix, Inc. Settles Litigation with Mati Therapeutics, Inc. BEDFORD, MASS. (BUSINESS WIRE) April 30, 2019 Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for di
Read more →OCULOcular Therapeutix Reports Fourth Quarter and Year End 2018 Financial Results and Business Update DEXTENZA Commercial Launch Planned for Mid-Year 2019 OTX-TP Phase 3 Data Expected in the First Half of 2019 Strengthened C
Ocular Therapeutix Reports Fourth Quarter and Year End 2018 Financial Results and Business Update DEXTENZA Commercial Launch Planned for Mid-Year 2019 OTX-TP Phase 3 Data Expected in the First Half of 2019 Strengthened Cash Position with Closing of $37.5 Million Financing BED
Read more →OCULOcular Therapeutix Reports Third Quarter 2018 Financial Results and Business Update DEXTENZA NDA Target PDUFA Action Date of
Ocular Therapeutix Reports Third Quarter 2018 Financial Results and Business Update DEXTENZA NDA Target PDUFA Action Date of December 28, 2018 BEDFORD, Mass. (BUSINESS WIRE) November 7, 2018 Ocular Therapeutix , Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the fo
Read more →OCULOcular Therapeutix Receives FDA Warning Letter Related to ReSure Sealant BEDFORD, Mass. (BUSINESS WIRE)
Ocular Therapeutix Receives FDA Warning Letter Related to ReSure Sealant BEDFORD, Mass. (BUSINESS WIRE) October 19, 2018 Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for
Read more →OCULOcular Therapeutix Reports Second Quarter 2018 Financial Results and Business Update DEXTENZA NDA Resubmission Submitted and Accepted by the U.S. Food and Drug Administration DEXTENZA Given
Ocular Therapeutix Reports Second Quarter 2018 Financial Results and Business Update DEXTENZA NDA Resubmission Submitted and Accepted by the U.S. Food and Drug Administration DEXTENZA Given December 28, 2018 Target PDUFA Date BEDFORD, Mass. (BUSINESS WIRE) August 7, 2018 Ocula
Read more →OCULOcular Drug Delivery Market is Expected to Reach $48,103 Million by 2025 - Progressive Markets
Pune, July 31, 2018 (GLOBE NEWSWIRE) -- Ocular drug delivery refers to the approaches used to deliver pharmaceutical compound in the eye to safely achieve its desired therapeutic effect. The major factor that contributes to the growth of the "ocular drug delivery market" include
Read more →OCULOcular Therapeutix Reports First Quarter 2018 Financial Results and Business Update Targeting DEXTENZA NDA Resubmission in the Second Quarter of 2018 BEDFORD, Mass. (BUSINESS WIRE)
Ocular Therapeutix Reports First Quarter 2018 Financial Results and Business Update Targeting DEXTENZA NDA Resubmission in the Second Quarter of 2018 BEDFORD, Mass. (BUSINESS WIRE) May 8, 2018 Ocular Therapeutix , Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the
Read more →OCULOcular Therapeutix Reports Fourth Quarter and Year End 2017 Financial Results and Business Update Anticipating DEXTENZA NDA Resubmission in the First Half of 2018 BEDFORD, Mass. (BUSINESS WIRE)
Ocular Therapeutix Reports Fourth Quarter and Year End 2017 Financial Results and Business Update Anticipating DEXTENZA NDA Resubmission in the First Half of 2018 BEDFORD, Mass. (BUSINESS WIRE) March 8, 2018 Ocular Therapeutix , Inc. (NASDAQ: OCUL), a biopharmaceutical company
Read more →OCULOcular Therapeutix Provides Legal Update
Ocular Therapeutix Provides Legal Update BEDFORD, Mass, December 22, 2017 - Ocular Therapeutix , Inc. (NASDAQ: OCUL) (the Company ), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of
Read more →OCULOcular Therapeutix Reports Third Quarter 2017 Financial Results and Provides Corporate Update Conference Call Today at 5:00pm Eastern Time
Ocular Therapeutix Reports Third Quarter 2017 Financial Results and Provides Corporate Update Conference Call Today at 5:00pm Eastern Time BEDFORD, Mass, November 7, 2017 - Ocular Therapeutix , Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufac
Read more →OCULOcular Therapeutix Reports Second Quarter 2017 Financial Results and Provides Corporate Update Conference Call Today at 5:00pm Eastern Time
Ocular Therapeutix Reports Second Quarter 2017 Financial Results and Provides Corporate Update Conference Call Today at 5:00pm Eastern Time BEDFORD, Mass, August 8, 2017 - Ocular Therapeutix , Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufact
Read more →OCULOCULAR THERAPEUTIX ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ocular Therapeutix, Inc. To Contact The Firm
NEW YORK, July 12, 2017 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (NASDAQ:OCUL) of the September 5, 2017 deadline to seek the role of lead plaintiff in a federal secu
Read more →OCULOcular Therapeutix Reports First Quarter 2017 Financial Results PDUFA Target Action Date of
Ocular Therapeutix Reports First Quarter 2017 Financial Results PDUFA Target Action Date of July 19, 2017 for the DEXTENZA NDA for the Treatment of Ocular Pain Following Ophthalmic Surgery; Commercial Launch Preparation Activities Underway Enrollment Continues in First Phase 3
Read more →OCULOcular Therapeutix Reports Fourth Quarter and Full Year 2016 Financial Results PDUFA Target Action Date of
Ocular Therapeutix Reports Fourth Quarter and Full Year 2016 Financial Results PDUFA Target Action Date of July 19, 2017 for the DEXTENZA NDA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery Enrollment Continues in the First Phase 3 Clinical Trial with OTX-TP
Read more →OCULOcular Therapeutix, Inc. Announces Public Offering of Common Stock
Ocular Therapeutix, Inc. Announces Public Offering of Common Stock BEDFORD, Mass. January 23, 2017 Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced today that it has commenced a registered underwritten public offering of $25 million of shares of its common stock pursuant to a
Read more →OCULOverview of Ocular Therapeutix We are a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using our proprietary hydrogel platform te
Overview of Ocular Therapeutix biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using our proprietary hydrogel platform technology. Our bioresorbable hydrogel-based drug product candidates
Read more →OCULOcular Therapeutix Reports Third Quarter 2016 Financial Results and Provides Corporate Update Preparing to Resubmit NDA for DEXTENZA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery to FDA by the End o
Ocular Therapeutix Reports Third Quarter 2016 Financial Results and Provides Preparing to Resubmit NDA for DEXTENZA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery to FDA by the End of 2016 Began Enrollment in First Phase 3 Clinical Trial with OTX-TP (Susta
Read more →OCULOcular Therapeutix Reports Second Quarter 2016 Financial Results and Provides Corporate Update Conference call today at 8:30 am Eastern Time
Ocular Therapeutix Reports Second Quarter 2016 Financial Results and Provides Corporate Update Conference call today at 8:30 am Eastern Time BEDFORD, Mass, August 9, 2016 (BUSINESS WIRE): Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the develop
Read more →OCULOcular Therapeutix Receives Complete Response Letter from FDA for its NDA for DEXTENZA for the Treatment of Post-Surgical Ocular Pain No efficacy or safety issues raised by FDA Outstanding items pertain to manufacturing
Ocular Therapeutix Receives Complete Response Letter from FDA for its NDA for DEXTENZA for the Treatment of Post-Surgical Ocular Pain No efficacy or safety issues raised by FDA Outstanding items pertain to manufacturing process and controls BEDFORD, Mass, July 25, 2016 (BUSIN
Read more →OCULOcular Therapeutix Announces Topline Results of Second Phase 3 Clinical Trial of DEXTENZA for the Treatment of Allergic Conjunctivitis Primary endpoint for ocular itching not achieved Conference call today at 8:30 am Eas
Ocular Therapeutix Announces Topline Results of Second Phase 3 Clinical Trial of DEXTENZA for the Treatment of Allergic Primary endpoint for ocular itching not achieved Conference call today at 8:30 am Eastern Time BEDFORD, Mass, June 6, 2016 (BUSINESS WIRE): Ocular Therapeuti
Read more →OCULOcular Therapeutix Reports First Quarter 2016 Financial Results and Provides Corporate Update PDUFA target action date of
Ocular Therapeutix Reports First Quarter 2016 Financial Results and Provides Corporate Update PDUFA target action date of July 24, 2016 for DEXTENZA NDA for the treatment of post-surgical ocular pain Second Phase 3 clinical trial for DEXTENZA for the treatment of allergic conju
Read more →OCULOcular Therapeutix TM Reports Fourth Quarter and Full Year 2015 Financial Results PDUFA target action date of
Ocular TherapeutixTM Reports Fourth Quarter and Full Year 2015 Financial action date of July 24, 2016 for the NDA for DEXTENZA for the treatment of post-surgical ocular pain; DEXTENZA advancing in late-stage clinical trials in multiple indications Initiation of Phase 3 clinical
Read more →OCULOcular Therapeutix, Inc. (Nasdaq: OCUL) to Ring the Nasdaq Stock Market Opening Bell
ADVISORY, Dec. 11, 2015 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq:OCUL), a biopharmaceutical company creating innovative therapies for diseases and conditions of the eye, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Dr. Amar Sawhney, Pr
Read more →OCULOcular Therapeutix Reports Third Quarter 2015 Financial Results Advances in Clinical Programs Include NDA Submission for DEXTENZA TM (sustained release dexamethasone, 0.4mg) for the Treatment of Post-Surgical Ocular Pain
Ocular Therapeutix Reports Third Quarter 2015 Financial Results Advances in Clinical Programs Include NDA Submission for DEXTENZATM (sustained release dexamethasone, 0.4mg) for the Treatment of Post-Surgical Ocular Pain Results Reported for Phase 3 Allergic Conjunctivitis and
Read more →OCULOcular Therapeutix TM Reports Second Quarter 2015 Financial Results Clinical Programs Advance with Patient Enrollment Finalized in Three Clinical Trials: Phase 3 Allergic Conjunctivitis Trial, Phase 2b Glaucoma Trial and
Ocular TherapeutixTM Reports Second Quarter 2015 Financial Results Clinical Programs Advance with Patient Enrollment Finalized in Three Clinical Trials: Phase 3 Allergic Conjunctivitis Trial, Phase 2b Glaucoma Trial and Phase 2 Inflammatory Dry Eye Trial Follow-on Public Offer
Read more →OCULOcular Therapeutix TM Announces Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication; Reports First Quarter 2015 Financial Results Company Provides Updates on Anticipat
Ocular TherapeutixTM Announces Plans to Proceed with an NDA Submission for OTX-DP for of Post-Surgical Ocular Pain Indication; Reports First Quarter 2015 Financial Results Company Provides Updates on Anticipated Clinical Milestones and Development Plans Conference Call Today a
Read more →OCULOcular Therapeutix Reports Fourth Quarter and Full Year 2014 Financial Results Both primary efficacy measures successfully achieved in the first of two Phase 3 clinical trials of OTX-DP for the treatment of post-surgical
Ocular Therapeutix Reports Fourth Quarter and Full Year 2014 Financial Results Both primary efficacy measures successfully achieved in the first of two Phase 3 clinical trials of OTX-DP for the treatment of post-surgical ocular inflammation and pain NDA submission for OTX-DP fo
Read more →OCULOcular Therapeutix Reports Third Quarter 2014 Financial Results Completed Enrollment for Sustained-Release Dexamethasone Phase 3 Clinical Trial in Post-Operative Ocular Inflammation and Pain First Patient Enrolled in the
Ocular Therapeutix Reports Third Quarter 2014 Financial Results Completed Enrollment for Sustained-Release Dexamethasone Phase 3 Clinical Trial in Post-Operative Ocular Inflammation and Pain First Patient Enrolled in the Sustained-Release Travoprost Phase 2b Clinical Trial for
Read more →OCULOcular Therapeutix Announces Second Quarter 2014 Financial Results BEDFORD, Mass. (BUSINESS WIRE)
Ocular Therapeutix Announces Second Quarter 2014 Financial Results BEDFORD, Mass. (BUSINESS WIRE) Aug. 28, 2014 Ocular Therapeutix (Nasdaq: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of
Read more →OCULOcular Therapeutix (NASDAQ: OCUL) to Ring The NASDAQ Stock Market Closing Bell
ADVISORY, July 31, 2014 (GLOBE NEWSWIRE) -- Ocular Therapeutix (Nasdaq:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, will visit the NASDAQ MarketSite in Times Square in celebrat
Read more →Competitive Position
How OCUL ranks across every disease it competes inCompetitive Position is a premium feature
See how OCUL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial